Novel Coronavirus Pneumonia (COVID-19)
Conditions
Interventions
Conventional treatment group:The conventional treatment group will be treated according to the guidance of the “Diagnosis and Treatment Scheme of COVID-19” published by the National Health Commission.
Experimental group:conventional treatment combined with Chloroquine Phosphate.
Sponsors
HwaMei Hospital, University of Chinese Academy of Sciences
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Patients aged 18 or older, and meet the diagnostic criteria of Diagnosis and Treatment Scheme of Novel Coronavirus Infected Pneumonia published by the National Health Commission. Criteria for diagnosis (meet all the following criteria): 1. With epidemiological history; 2. Clinical manifestations (meet any 2 of the following): fever, normal or decreased white blood cell count or lymphopenia in the early stage of onset, and Chest radiology in the early stage shows multiple small patchy shadowing and interstitial changes which is especially significant in periphery pulmonary. Furthermore, it develops into bilateral multiple ground-glass opacity and infiltrating shadowing. Pulmonary consolidation occurs in severe cases. Pleural effusion is rare; 3. Confirmed case (suspected case obtained one of the following etiologic evidences): a positive result to real-time reverse-transcriptase PCR for respiratory specimen or blood specimen, or Genetic sequencing result of virus in respiratory or blood specimens are highly homologous to SARS-CoV-2.
Exclusion criteria
Exclusion criteria: 1. Female patients during pregnancy; 2. Patients with known allergy to chloroquine; 3. Patients with haematological diseases; 4. Patients with chronic liver or kidney diseases at the end stage; 5. Patients with arrhythmia and chronic heart disease; 6. Patients with retinal disease, hearing deficiency or hearing loss; 7. Patients with psychiatric diseases; 8. Patients taking digitalis due to underlying diseases.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Length of hospital stay; | — |
Secondary
| Measure | Time frame |
|---|---|
| Length from the day of admission to the day returning to normal body temperature, from admission to two consecutive negative results of respiratory pathogenic nucleic acid test (sampling interval of at least 1 day), and from admission to the chest CT shows significant improvement.;The proportion of cases transformed from mild to severe illness;30-day etiologic mortality;30-days all-cause mortality;Proportion of relapse within 14 days after discharge (relapse refers to positive result of respiratory pathogenic nucleic acid test, and/or worsening lesions in chest CT).;C-reactive protein;Inflammatory factors (including IL-2, IL-4, IL-6, IL-10, TNF-alpha, TFN-gama, etc.) and lymphocyte sub-groups; | — |
Countries
China
Contacts
Public ContactTing Cai
HwaMei Hospital, University of Chinese Academy of Sciences
Outcome results
None listed